Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $1.2 million.

  • GeneDx Holdings' Gains from Investment Securities rose 31.59% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 66.55%. This contributed to the annual value of $13.4 million for FY2024, which is 271.60% up from last year.
  • GeneDx Holdings' Gains from Investment Securities amounted to $1.2 million in Q3 2025, which was up 1,767.74% from $62,000 recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Gains from Investment Securities registered a high of $81.7 million during Q3 2021, and its lowest value of -$76.2 million during Q4 2021.
  • In the last 3 years, GeneDx Holdings' Gains from Investment Securities had a median value of $1.2 million in 2025 and averaged $1.8 million.
  • As far as peak fluctuations go, GeneDx Holdings' Gains from Investment Securities slumped by 297.95% in 2021, and later soared by 297.62% in 2024.
  • Over the past 5 years, GeneDx Holdings' Gains from Investment Securities (Quarterly) stood at -$76.2 million in 2021, then spiked by 79.17% to -$15.9 million in 2022, then spiked by 109.23% to $1.5 million in 2023, then surged by 35.15% to $2.0 million in 2024, then spiked by 31.59% to $1.2 million in 2025.
  • Its Gains from Investment Securities stands at $1.2 million for Q3 2025, versus $62,000 for Q2 2025 and $1.1 million for Q1 2025.